|
1
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schwartz PE: Current diagnosis and
treatment modalities for ovarian cancer. Cancer Treat Res.
107:99–118. 2002.PubMed/NCBI
|
|
4
|
Basu-Roy U, Bayin NS, Rattanakorn K, Han
E, Placantonakis DG, Mansukhani A and Basilico C: Sox2 antagonizes
the Hippo pathway to maintain stemness in cancer cells. Nat Commun.
6:64112015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu AM, Xu MZ, Chen J, Poon RT and Luk JM:
Targeting YAP and Hippo signaling pathway in liver cancer. Expert
Opin Ther Targets. 14:855–868. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pegoraro S, Ros G, Ciani Y, Sgarra R,
Piazza S and Manfioletti G: A novel HMGA1-CCNE2-YAP axis regulates
breast cancer aggressiveness. Oncotarget. 6:19087–19101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu H, Wei L, Fan F, Ji S, Zhang S, Geng J,
Hong L, Fan X, Chen Q, Tian J, et al: Integration of Hippo
signalling and the unfolded protein response to restrain liver
overgrowth and tumorigenesis. Nat Commun. 6:62392015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao Y, Zhang W, Han X, Li F, Wang X, Wang
R, Fang Z, Tong X, Yao S, Li F, et al: YAP inhibits squamous
transdifferentiation of Lkb1-deficient lung adenocarcinoma through
ZEB2-dependent DNp63 repression. Nat Commun. 5:46292014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang X, George J, Deb S, Degoutin JL,
Takano EA, Fox SB, Bowtell DD and Harvey KF; AOCS Study Group, :
The Hippo pathway transcriptional co-activator, YAP, is an ovarian
cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He C, Lv X, Hua G, Lele SM, Remmenga S,
Dong J, Davis JS and Wang C: YAP forms autocrine loops with the
ERBB pathway to regulate ovarian cancer initiation and progression.
Oncogene. 34:6040–6054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei X, Liu Y, Gong C, Ji T, Zhou X, Zhang
T, Wan D, Xu S, Jin P, Yang X, et al: Targeting leptin as a
therapeutic strategy against ovarian cancer peritoneal metastasis.
Anticancer Agents Med Chem. 17:1093–1101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F,
Ding W, Wang J, Xia X, Li F, et al: Abrogation of constitutive
Stat3 activity circumvents cisplatin resistant ovarian cancer.
Cancer Lett. 341:231–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gyorffy B, Lanczky A and Szallasi Z:
Implementing an online tool for genome-wide validation of
survival-associated biomarkers in ovarian-cancer using microarray
data from 1287 patients. Endocr Relat Cancer. 19:197–208. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, Pan P, Wang Z, Zhang Y, Xie P,
Geng D, Jiang Y, Yu R and Zhou X: β-catenin-mediated YAP signaling
promotes human glioma growth. J Exp Clin Cancer Res. 36:1362017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma Y, Yang Y, Wang F, Wei Q and Qin H:
Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int
J Cancer. 137:2275–2286. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hua G, Lv X, He C, Remmenga SW, Rodabough
KJ, Dong J, Yang L, Lele SM, Yang P, Zhou J, et al: YAP induces
high-grade serous carcinoma in fallopian tube secretory epithelial
cells. Oncogene. 35:2247–2265. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang EY, Cheng JC, Thakur A, Yi Y, Tsai SH
and Hoodless PA: YAP transcriptionally regulates ErbB2 to promote
liver cell proliferation. Biochim Biophys Acta Gene Regul Mech. Jul
17–2018.(Epub ahead of print) doi: 10.1016/j.bbagrm.2018.07.004.
View Article : Google Scholar
|
|
19
|
Liu M, Lin Y, Zhang XC, Tan YH, Yao YL,
Tan J, Zhang X, Cui YH, Liu X, Wang Y and Bian XW: Phosphorylated
mTOR and YAP serve as prognostic markers and therapeutic targets in
gliomas. Lab Invest. 97:1354–1363. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tutt A, Robson M, Garber JE, Domchek SM,
Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler
RK, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in
patients with BRCA1 or BRCA2 mutations and advanced breast cancer:
A proof-of-concept trial. Lancet. 376:235–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dowell JE and Minna JD: EGFR mutations and
molecularly targeted therapy: A new era in the treatment of lung
cancer. Nat Clin Prac Oncol. 3:170–171. 2006. View Article : Google Scholar
|
|
23
|
Zhang Z, Lin Z, Zhou Z, Shen HC, Yan SF,
Mayweg AV, Xu Z, Qin N, Wong JC, Zhang Z, et al: Structure-Based
design and synthesis of potent cyclic peptides inhibiting the
YAP-TEAD protein-protein interaction. ACS Med Chem Lett. 5:993–998.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou Z, Hu T, Xu Z, Lin Z, Zhang Z, Feng
T, Zhu L, Rong Y, Shen H, Luk JM, et al: Targeting Hippo pathway by
specific interruption of YAP-TEAD interaction using cyclic YAP-like
peptides. FASEB J. 29:724–732. 2015. View Article : Google Scholar : PubMed/NCBI
|
